Roswell Park Accelerates CAR T-Cell Innovation with Upcoming Trials - Takeaways - MDSpire

Roswell Park Accelerates CAR T-Cell Innovation with Upcoming Trials

Renier Brentjens, MD, PhD, has spent most of his career pioneering research into the development and use of CAR T-cell therapies in the hopes of finding innovative and effective treatments for cancer.

  • February 18, 2025

Share

  • 1

    Renier Brentjens, MD, PhD, leads CAR T-cell therapy innovations at Roswell Park Comprehensive Cancer Center.

  • 2

    Upcoming clinical trials at Roswell Park will target osteosarcoma, small-cell lung cancer, and ovarian cancer.

  • 3

    CAR T-cell therapy has shown success in blood cancers but requires further development for solid tumors.

  • 4

    Roswell Park has expanded its capacity to transition CAR T-cell technology from laboratory to clinical settings.

  • 5

    The center collaborates with other institutions and biotech companies to enhance CAR T-cell therapy advancements.

Original Source(s)

Roswell Park Accelerates CAR T-Cell Innovation with Upcoming Trials

  • February 18, 2025

Related Content

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases